Dr
Inge
Muellejans

European Patent Attorney

Edinburgh Office Glasgow Office

Chemistry

Telephone. +44(0) 131 220 7500
Mobile. +44(0) 786 719 8074
Email. [email protected]

Experience

Specialising in the field of chemistry, particularly medical devices, fibres, fabrics, personal care and cosmetics, Inge has over 20 years of experience in the patent profession both in-house and in private practice. She deals with all IP related topics, in particular drafting and prosecuting patent applications, EPO opposition and appeal proceedings, opinions on freedom-to-operate and validity as well as IP strategy and portfolio management.

Inge has extensive experience dealing with freedom-to-operate, infringement and validity opinions which she partly obtained during the 11 years she worked in-house for a leading specialty chemical company in Germany. She has a broad range of expertise handling oppositions and appeals at the EPO as well as drafting and prosecuting patent applications worldwide.

In addition, she has managed global patent portfolios both in private practice and in-house providing strategic advice to patent professionals, marketing and application technology leaders. She also advises on the German law for employee’s inventions.

Inge graduated at RWTH Aachen University in Germany and obtained a PhD in Chemistry at the DWI Aachen while working on projects for the German Federation of Industrial Research Associations (AIF).

After two years of running the search department of a leading personal healthcare company, Inge joined a specialty chemical company where she qualified as a European Patent Attorney. She moved to Scotland in 2012 to work in private practice, before joining the Edinburgh office of HGF in January 2016.

Qualifications

Patent Attorney

European


BSC

RWTH Aachen

MSC

RWTH Aachen

PHD

RWTH Aachen

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.